A prospective study of female hormone use and breast cancer among black women

Archives of Internal Medicine

Volumn 166, Issue 7, 2006, Pages 760-765

  Rosenberg, Lynn ^a   Palmer, Julie R ^a   Wise, Lauren A ^a   Adams Campbell, Lucile L ^b  

^a BOSTON UNIVERSITY   (United States)

^b HOWARD UNIVERSITY CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BREAST CANCER; CALCULATION; CANCER INCIDENCE; CANCER RISK; CONFIDENCE INTERVAL; DRUG UTILIZATION; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AFRICAN AMERICANS; AGED; BODY MASS INDEX; BREAST NEOPLASMS; EDUCATIONAL STATUS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 33645738056     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.7.760     Document Type: Article

References (37)

1. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev. 1993;15:66-79.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
3. La Vecchia C. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer. Breast. 2004;13:515-518.
4. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-427.
5. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485-491.
6. Magnusson C, Baron JA, Correia N, et al. Breast cancer risk following long-term estrogen and estrogen-progestin-replacement therapy. Int J Cancer. 1999;81:339-344.
7. Persson I, Weiderpass E, Bergkvist L, Bergström R, Shairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10:253-260.
8. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92:328-332.
9. Kirsh V, Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control. 2002;13:583-590.
10. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapies and breast cancer risk. Obstet Gynecol. 2002;100:1148-1158.
11. Porch JV, Lee I-M, Cook NR, et al. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control. 2002;13:847-854.
12. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-741.
13. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289:3254-3263.
14. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004;109:721-727.
15. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
16. Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
17. Pike MC, Kolonel LN, Hendersen BE, et al. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002;11:795-800.
18. Hall IJ, Moorman PG, Millikan RC, Newman B. Comparative analysis of breast cancer risk factors among African-American women and White women. Am J Epidemiol. 2005;161:40-51.
19. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97:439-448.
20. Ursin G, Bernstein L, Wang Y, et al. Reproductive factors and risk of breast carcinoma in a study of white and African-American women. Cancer. 2004;101:353-362.
21. Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Schoenberg JB. Ethnicity and variation in breast cancer incidence. Int J Cancer. 1997;73:349-355.
22. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
23. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
24. Palmer JR, Wise LA, Adams-Campbell LL, Rosenberg L. A prospective study of induced abortion and breast cancer in African-American women. Cancer Causes Control. 2004;15:105-111.
25. Therneau TM. Extending the Cox model. In: Lin DY, Fleming TR, eds. Proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis. New York, NY: Springer-Verlag; 1997.
26. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc; 1995.
27. Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol. 1998;147:718-721.
28. Hulley S, Ferber C, Barrett-Connor E, et al; HERS Research Group. Noncardiovascular outcomes during 6.8 years of hormone therapy: Heart and Estrogen Replacement Study Follow-up (HERS II). JAMA. 2002;288:58-66.
29. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal female hormone users in a screened population. J Clin Oncol. 2003;21:4314-4321.
30. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253.
31. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1993;15:48-65.
32. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606-616.
33. Pike MC, Spice DV, Dahmoush L, Press MF. Estrogen, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17-35.
34. Ferguson DJP, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer. 1981;44:177-179.
35. Gajdos C, Tartter PI, Babinski A. Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol. 2000;95:513-518.
36. Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known risk factors and increase risk of breast cancer? J Clin Oncol. 2002;20:699-706.
37. US Census Bureau. Educational attainment in the United States: March 1998 (update) (Current Population Reports P20-543). Washington, DC: US Dept of Commerce; 1998.